GlassScriptPhysician profile
Mladjen Veselinovic
NPI 1427430214
$1,163.53
in general payments reported to CMS, 2019-2025
19 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.89 · 2022: $154 · 2023: $454 · 2024: $414 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $213.18 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Abbvie INC. | $148.18 | 2022-2024 | Avycaz, Mavyret |
| Theratechnologies INC. | $138.42 | 2023-2024 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $132.44 | 2022-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $88.81 | 2023-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Mallinckrodt Hospital Products INC. | $73.08 | 2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.74 | 2024 | Stiolto Respimat, Spiriva Respimat |
| Shionogi INC | $50.86 | 2023 | Fetroja |
| United Therapeutics Corporation | $47.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.65 | 2022-2024 | Xarelto |
| Gilead Sciences, INC. | $39.75 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.82 | 2019 | |
| Insmed, INC. | $17.96 | 2025 | Arikayce |
| Viiv Healthcare Company | $15.40 | 2024 | Dovato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $15.36 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $14.07 | 2019 | |
| Nevro Corp. | $13.26 | 2023 | Senza |
| Glaxosmithkline, LLC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mladjen Veselinovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.